Controversies about the choice of antibiotic agent and treatment modality exist in the management of erythema migrans in early cutaneous Lyme borreliosis (LB).
L yme borreliosis (LB) is a disease caused by the spirochete Borrelia burgdorferi and transmitted by tick bites in most northern hemisphere countries of Europe, North America, and Asia. [1] [2] [3] [4] [5] Countries in Western Europe have a large variance in incidence rates. The highest rates of LB have been reported in southern Sweden, with 464 per 100 000 personyears, and the lowest rates have been reported in Italy, with 0.001 per 100 000 person-years. 6 The population-weighted incidence rate in Western Europe has been estimated by 1 study 6 to be 22.04 per 100 000 person-years.
Early localized manifestations of LB include erythema migrans (EM) and, more seldom, borrelial lymphocytoma. Erythema migrans is detected in approximately 70% to 90% of patients with LB 7-10 and can have a range of appearances, including the classic bull's-eye lesion, but atypical lesions are also common. [11] [12] [13] [14] [15] Erythema migrans typically occurs at the site of the tick bite 3 to 32 days after the bite. 12, 14, 16 Most individuals show a single lesion although approximately 10% to 20% of patients with LB show multiple EM lesions (MEM), which are caused by hematogenic dissemination of the bacteria via the bloodstream into the skin. Early disseminated manifestations of LB include neuroborreliosis (affecting 10%-20% of patients with LB) 3, 9 and heart problems (affecting 4%-10% of patients with LB). 17 Late manifestations (affecting 2%-10% of patients with LB) may involve the joints 18 but may also involve the nervous system or the skin. Lyme borreliosis has a substantial disease burden of 10.6 disability-adjusted life-years (DALYs) per 100 000 persons based on the incidence rate in northern Europe (Netherland) in 2010, with 9.1 DALYs for persisting symptoms, 0.9 DALYs for disseminated LB, and 0.6 DALYs for EM. 19 Compared with other more common cutaneous diseases, EM has a low disease burden. For example, an update from the Global Burden of Disease Study 2013 20 reported 55 DALYs for viral skin diseases and 16 DALYs for cellulitis.
Patients with early cutaneous manifestations of LB are generally treated with antibiotics to eliminate the spirochete to cure immediate disease and to prevent late manifestations. The broadspectrum antibiotic doxycycline is the mainstay of therapy for cutaneous manifestations of LB. 21 Other first-line antibacterial agents are phenoxymethylpenicillin (also known as penicillin V), amoxicillin, or cefuroxime axetil. [22] [23] [24] However, some treatment failures have been reported with all antibiotic agents in use. [25] [26] [27] In particular, undertreated infections may resurface and result in progression and dissemination to other organs, especially the nervous system and joints, causing long-term morbidity and costs. [28] [29] [30] Hence, the aim of the present study was to conduct a systematic review of all randomized clinical trials focused on treatment response and drug-related adverse outcomes of various antibiotic regimens in adults with early cutaneous LB to provide evidence for the development of clinical practice guidelines and individual patient decision making.
Methods

Reporting Guideline and Protocol
This research was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension statement for systematic reviews incorporating network meta-analyses (NMA) of health care interventions (eAppendix 1 in the Supplement).
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The methods of this systematic review were prespecified in a protocol published in 2016. 32 Modifications to that protocol are described in eAppendix 2 in the Supplement.
Search Strategies and Inclusion Criteria
To identify eligible studies, we conducted electronic searches in Ovid MEDLINE, Ovid MEDLINE in Process & Other Non-Indexed Citations, Ovid MEDLINE daily update, Ovid Embase, and the Cochrane Central Register of Controlled Trials (via the Cochrane Library) from inception until November 2015. An update search was performed July 2017. The search strategy was based on combinations of medical subject headings and keywords and was not restricted to any specific language. The search strategy used in Ovid MEDLINE is given in eAppendix 3 in the Supplement. Search strategies for the other databases were modified to meet the requirements of each database. In addition, we hand-searched reference lists of included studies and contacted authors. Searches for ongoing trials or trials completed but not published were conducted on ClinicalTrials.gov and the World Health Organization's International Clinical Trials Registry Platform. 33 One reviewer (G.T.) screened the titles and abstracts of all references identified by electronic searches. We obtained fulltext copies of all potentially relevant articles, and 2 reviewers (G.T., H.H., K.B., M.H.F., or C.S.) independently assessed those articles for inclusion. Conflicts were resolved by discussion. The randomized clinical trials considered for this review included those studying adults with a clinically (physicianconfirmed) early localized skin infection who were treated with antibiotics of any dose for any duration.
Data Extraction
We extracted data on patients (eg, number of patients included and randomized, and the proportion of patients receiving a diagnosis of EM or MEM), interventions (eg, antibiotic agent, dosage, length of treatment), and outcomes (response to treatment and any treatment-related adverse event). For the outcome "response to treatment," we conducted 2 analyses. First, we combined complete responders and partial responders and compared them with treatment failures (persistent EM, disseminated disease, or both). We then combined partial responders and treatment failures and compared them with complete responders. The definition and assessment of response to treatment as described in the individual studies are given in eTable 1 in the Supplement. All reported adverse events were extracted according to the definitions of the primary studies, and individual participants served as the unit of analysis. Because repeated adverse events can occur in the same participant, we considered the number of individuals with at least 1 event of a type, rather than the total number of any adverse event. In addition, we also categorized all adverse events involving the skin or gastrointestinal tract or hematologic or Jarisch-Herxheimer-like reactions using the individual participant as the unit of analysis. Outcome data for which only the number of events, and not the number of participants, was reported were not included.
Risk of Bias and Grading of Recommendations Assessment, Development, and Evaluation
Risk of bias was assessed according to the method described in the Cochrane Handbook for Systematic Reviews of Interventions. 34 The following domains were considered: randomization sequence generation; allocation concealment; masking (blinding) of participants, trial personal, and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias (ie, bias due to problems not covered elsewhere). The certainty of evidence for the outcomes response to treatment (≥12 months following start of treatment) and any treatment-related adverse event was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for NMA, which is associated with specific comparisons, including estimates from direct and indirect comparisons. 35, 36 In brief, our certainty assessment addressed study limitations (risk of bias), incoherence (differences between direct and indirect estimates of effect as defined by the P values of z tests and the size and overlap of 95% CIs of direct and indirect estimates), imprecision (95% CIs that were wide or included or were close to a null effect around the point estimate from the indirect comparison), inconsistency (differences in estimates of effect across studies that assessed the same comparison), and indirectness (in an NMA, indirectness expresses concerns from indirect comparisons, a so-called intransitivity measure). 35,37 Indirect estimates were potentially further downgraded for intransitivity (ie, differences in patient characteristics, differing (co-) intervention, differing extent to which intervention of interest was optimally administered, differing comparator, and differences in measurement of outcome). In the event of coherent direct and indirect effect estimates, the higher rating was assigned to the NMA estimate. On the basis of these criteria, the certainty of the evidence for each comparison and outcome was categorized as high, moderate, low, or very low. The results for the response to treatment outcome are presented for both short-term (≤2 months following start of treatment) and long-term follow-up (≥12 months following start of treatment). Treatment effects are expressed as odds ratios (ORs) with 95% CIs. Overall, when significant heterogeneity was found among comparable studies (I 2 for heterogeneity >50%), pooled estimates were not provided (which was, however, not the case in the present study). Data for the response to treatment outcome were analyzed, if possible, on an intention-to-treat basis. 47 For adverse events, we conducted a complete case analysis (ie, including only participants assessed at each specific follow-up time).
Results
Literature Search and Selection Process
After elimination of duplicates among databases, we screened 9975 references, of which the full text was evaluated for 161 references ( Figure 1 ). We included 19 randomized clinical trials (2532 patients) that compared different antibiotic agents, treatment strategies, or both, of which 17 studies were included in the NMA.
23,48-65
Study Characteristics
The main study characteristics are presented in eTable 2 in the Supplement. Across trials, the mean patient age ranged between 37 and 56 years, and the percentage of female patients ranged from 36% to 60%. e Downgraded once for serious study limitations (risk of bias particularly due to high or unclear risk of selection bias and/or lack of blinding).
f Downgraded once for serious imprecision (wide confidence interval due to small sample size).
g Downgraded once for serious intransitivity (comparable with indirectness in pairwise meta-analyses due to differences in the participants, interventions, and outcome measurements).
h Downgraded once for serious indirectness.
i Cannot be estimated because the drug was not connected in a loop in the evidence network.
j For approximately 15% of patients, treatment response could not be categorized.
k Patients: 1793; setting: hospitals in the United States (6 studies), Slovenia (3 studies), Austria (1 study), Germany (2 studies), Croatia (1 study), and Norway (1 study); interventions: (irrespective of dose and duration) amoxicillin, amoxicillin plus probenecid, azithromycin, ceftriaxone, cefuroxime axetil, ceftriaxone plus doxycycline, minocycline, and penicillin V; comparison: doxycycline (irrespective of dose and duration).
Research Original Investigation
Efficacy and Safety of Antibiotic Therapy in Early Cutaneous Lyme Borreliosis follow-up from treatment initiation was 12 months (range, 6 weeks to 30 months). All studies were active comparator studies, that is, none included a placebo control. Doxycycline (administered at various dosages and durations) was the most frequently investigated drug, with 909 patients assigned. 
Assessment of Risk of Bias
The results of the risk of bias assessment are provided in Figure 2 . Five studies were judged to have a high risk of selection bias because of major limitations in the randomization process.
48-51,63
In another 4 studies, patients, clinicians, and outcome assessors were aware of the treatment group, leading to a high risk of performance and detection bias. 52,59,61,64 Five studies were associated with a low risk of bias for random sequence generation and adequate blinding of outcome assessors.
53,54,56,60,65
Selective reporting could not be sufficiently assessed because of missing information regarding important outcome measures (ie, no study protocol was prepublished, or outcome measures were neither predefined nor clearly described). Five studies were poorly reported overall, making an adequate risk of bias assessment impossible.
23,55,57,58,62
Response to Treatment
When antibiotic agents were compared irrespective of dose and duration, pooled effect sizes did not suggest significant differences in treatment response among agents for up to 2 months after treatment initiation (10 studies, 8 agents [nodes], and 1435 patients) 17 ,24,48,52-56,59,61 nor at 12 or more months after treatment initiation (6 studies, 6 agents [nodes], 908 patients, and low and very low certainty) ( Figure 3Aa n d Table) . 48, 50, 59, 60, 63, 65 Overall, more than 80% of patients showed a treatment response, 84% (95% CI, 80%-88%) at 2 or fewer months after treatment initiation and 80% (95% CI, Figure 3B and Table) . Any Skin-Related Adverse Event
The percentage of patients with skin-related adverse events, such as photosensitivity, photodermatitis, or urticaria, was 3% (95% CI, 2%-6%) of patients. Irrespective of dose and duration, compared with doxycycline, cefuroxime axetil showed a significantly lower risk of skin reaction (OR, 0.18; 95% CI, 0.07-0.52; 9 studies, 6 agents [nodes], and 1211 patients; Figure 3C ). Any Hematologic Adverse Event
The percentage of patients with hematologic adverse events, such as thrombocytopenia, was 1% (95% CI, 0%-3%). An NMA conducted irrespective of dosage and duration showed no difference among the antibiotic agents (3 studies, 3 agents [nodes], and 437 patients; Figure 4B ). There was also no difference for hematologic adverse outcome when different treatment modalities were considered within pairwise metaanalyses ( 
Jarisch-Herxheimer-Like Reaction
Jarisch-Herxheimer-like reaction occurred in 15% (95% CI, 11%-20%) of patients. No differences were identified in the comparison of agents irrespective of dose and duration (7 studies, 7 agents [nodes], and 710 patients; Figure 4C ). 
Discussion
Main Findings
This NMA addressed treatment response and risk of treatmentrelated adverse events following treatment of EM in early cutaneous LB with various antibiotic agents and treatment regimens. The studies were conducted in the United States or in various European countries. Despite differences in the spectrum of pathogens that may be present in different regions and given the extended study period of more than 25 years, the results were generally consistent across the trials, suggesting good applicability of the evidence in countries with high risk of borreliosis.
When antibiotic agents were compared irrespective of dose and duration, pooled effect sizes revealed no differences in response to treatment among the interventions up to 2 months following treatment initiation nor at 12 or more months following treatment initiation. In addition, different antibiotic treatment modalities (including 10, 14-15, and 21 days of doxycycline administration) did not differently contribute to EM resolution or the reduction of associated symptoms. Overall, treatment failures were rare (<5%), and most participants enrolled in the examined studies had good clinical outcomes regardless of the antibiotic agent administered or treatment modality used. Treatment-related adverse outcomes occurred in approximately 35% of patients, but the majority of those events were mild. Overall, penicillin V, regardless of dosage and treatment duration, was the antibiotic with the lowest risk of any adverse event (the reduction in effect size compared with that for doxycycline was 58%). Photosensitivity was the most commonly reported skin-related adverse event, and this occurred only in patients who used doxycycline. However, the low or very low certainty of evidence precludes any further speculation. Additional analyses considering different dosage and duration treatment modalities, including an extended treatment regimen of doxycycline for 3 weeks compared with that for 2 weeks, did not show significant differences in drug-related adverse outcomes (eFigure 2 in the Supplement).
The overall certainty of evidence was generally low, occasionally very low, meaning that further research is likely to change the estimate of effects. The major issues were wide confidence intervals (imprecision), indirectness and study limitations (high risk of bias) due to inadequate randomization and the lack of blinding of patients, health care professionals who administered treatment, and outcome assessors. Poor reporting of the included studies made the interpretation of the evidence additionally challenging.
Limitations
Overall, NMA provides a useful tool for comparing several competing interventions to develop evidence-based clinical guidelines. However, some challenges exist in network connectivity, consistency, and similarity of studies for the study design, settings, patients and (co)-interventions. Although statistical heterogeneity was low, studies differed particularly in baseline characteristics, including the duration of EM, the inclusion patients of with symptoms additional to EM, study settings, and follow-up times; the contribution of these differences to treatment outcomes was unknown. Another issue may be the potentially unclear validity of the clinical diagnosis of EM. We included studies that used a clinical diagnosis of EM for patient enrollment, and this was often described only as physician-documented EM; thus, we had to rely on the authors' reports. The same issue was true for concomitant symptoms of the disease. It may be difficult for patients and clinicians to differentiate drug-related adverse events from concomitant symptoms of the disease, such as joint pain, neck stiffness, headache, tiredness, or myalgia, resulting in treatment failures. In addition, patient data for treatment responders and failures were not always sufficiently reported and thus could not be categorized and are lacking in the present analysis. Therefore, the corresponding results on response to treatment could be overestimated or even underestimated. The lack of a placebo group prevented assessment of the efficacy of drug treatment when compared with the natural course of disease. Our review was therefore able to only summarize outcome data for comparative effectiveness of antibiotics (relative efficacy) when used for the treatment of EM.
Patients with neuroborreliosis and damage of the nervous system may need to be treated different from patients with early cutaneous LB. A former review from our group 67 and a Cochrane review 68 addressing these patient populations concluded that there is a lack of well conducted controlled published studies. Therefore, currently, it is not possible to draw firm conclusions on the relative efficacy of accepted antibiotic drug regimens for the treatment of neuroborreliosis or neurologic manifestations. However, the majority of patients included in the assessed trials showed good outcomes, with symptoms resolving by 12 months of treatment initiation regardless of the antibiotic used.
Comparison With Other Reviews or Guidelines
Numerous systematic reviews and guidelines addressing the management of EM exist. 17 , which directly compares doxycycline and amoxicillin. Conducting an NMA based on the best currently available evidence allowed us to perform quantitative analyses of interventions compared directly in head-to-head studies and of interventions that have not been directly compared in studies. This methodological approach is pivotal to guideline development in the absence of adequate head-tohead comparator evidence. 72 Nonetheless, an NMA is not a substitute for a well-conducted randomized clinical trial.
Conclusions
Treatment failures were rare regardless of antibiotic agent or treatment regimen used. There was no high-certainty evidence that extended treatment schemes with doxycycline enhanced therapeutic efficacy in patients with early cutaneous LB. Placebo-controlled studies are not in line with ethical standards; therefore, a comparison between antibiotic treatment and no antibiotic treatment was not feasible in this patient population. The reasons for the designations of low or very low certainty for the relative efficacy and safety in our NMA were imprecision, risk of bias, and indirectness. Rigorously conducted studies with adequate sample size are needed to identify possible smaller differences in comparative effectiveness and to rule out relevant drug-related safety issues. 
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Objectives 4
Provide an explicit statement of questions being addressed, with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
METHODS
Protocol and registration 5
Indicate whether a review protocol exists and if and where it can be accessed (e.g., Web address); and, if available, provide registration information, including registration number.
7
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. Clearly describe eligible treatments included in the treatment network, and note whether any have been clustered or merged into the same node (with justification).
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
and eMethods 3
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
7
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from 7-8 investigators.
Data items 11
List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
8
Geometry of the network
S1
Describe methods used to explore the geometry of the treatment network under study and potential biases related to it. This should include how the evidence base has been graphically summarized for presentation, and what characteristics were compiled and used to describe the evidence base to readers.
9,10
Risk of bias within individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
8,9
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). Also describe the use of additional summary measures assessed, such as treatment rankings and surface under the cumulative ranking curve (SUCRA) values, as well as modified approaches used to present summary findings from meta-analyses.
9,10
Planned methods of analysis
14
Describe the methods of handling data and combining results of studies for each network meta-analysis. This should include, but not be limited to: Handling of multiarm trials; Selection of variance structure; Selection of prior distributions in Bayesian analyses; and Assessment of model fit.
9,10
Assessment of Inconsistency
S2
Describe the statistical methods used to evaluate the agreement of direct and indirect evidence in the treatment network(s) studied. Describe efforts taken to address its presence when found.
9,10
Risk of bias across studies
15
Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
8,9
Additional analyses 16 Describe methods of additional analyses if done, indicating which were pre-specified. This may include, but not be limited to, the following:
• Sensitivity or subgroup analyses;
• Meta-regression analyses;
• Alternative formulations of the treatment network; and • Use of alternative prior distributions for Bayesian analyses (if applicable).
9,10 and eMethods 2 RESULTS
Study selection 17
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. Figure 1 Presentation of network structure
and
S3
Provide a network graph of the included studies to enable visualization of the geometry of the treatment network.
Figure 3
Summary of network geometry
S4
Provide a brief overview of characteristics of the treatment network. This may include commentary on the abundance of trials and randomized patients for the different interventions and pairwise comparisons in the network, gaps of evidence in the treatment network, and potential biases reflected by the network structure.
12-14
Study characteristics
18
For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
and eTable 1/2
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment.
11,12 and Figure 2
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: 1) simple summary data for each intervention group, and 2) effect estimates and confidence intervals. Modified approaches may be needed to deal with information from larger networks. Table 1 Risk of bias across studies
12-15 and
22
Present results of any assessment of risk of bias across studies for the evidence base being studied.
Table 1
Results of additional analyses
23
Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression analyses, alternative network geometries studied, alternative choice of prior distributions for Bayesian analyses, and so forth).
Not applicable
DISCUSSION
Summary of evidence 24
Summarize the main findings, including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy-makers).
16
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias). Comment on the validity of the assumptions, such as transitivity and consistency. Comment on any concerns regarding network geometry (e.g., avoidance of certain comparisons).
17
Conclusions 26
Provide a general interpretation of the results in the context of other evidence, and implications for future research.
18/19
FUNDING Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. This should also include information regarding whether funding has been received from manufacturers of treatments in the network and/or whether some of the authors are content experts with professional conflicts of interest that could affect use of treatments in the network.
20
PICOS; population, intervention, comparators, outcomes, study design. a Text in italics indicates wording specific to reporting of network meta-analyses that has been added to guidance from the PRISMA statement.
Reference eAppendix 3. Search Strategy Database(s) in MEDLINE(R) (via Ovid on 2015-11-24)
